Lupin has informed that it enclosed is a Press Release as regards launch of Molnupiravir by the Company under the brand name Molnulup for the treatment of COVID-19 in adults in India. This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.